Search research articles
Contact Us
Filters
Showing results (181-190 of 677) with videos related to
Page
of 68
Sort By:
Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology
|
January 1, 1979
Blood coagulation and platelet function: introduction
B B Vargaftig, J Conard, M Samama
Journal Des Maladies Vasculaires
|
November 1, 1996
[Forensic medical implications of anticoagulant treatments]
M Samama, J C Valdes, J Natali
British Journal of Haematology
|
March 2, 1999
Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
L Bara, A Planes, M M Samama
International Angiology : a Journal of the International Union of Angiology
|
March 1, 1995
Red cell aggregability increases with the severity of venous insufficiency
A Chabanel, F Zuccarelli, M M Samama
Thrombosis Research
|
September 1, 1991
Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro
A M Dosne, F Dubor, M Samama
Annales De Medecine Interne
|
January 1, 1986
[Treatment of deep venous thromboses with heparin. Therapeutic management and biological monitoring]
J Conard, M H Horellou, M Samama
Acta Chirurgica Scandinavica. Supplementum
|
January 1, 1988
Incidence of thromboembolism in association with congenital disorders in coagulation and fibrinolysis
J Conard, M H Horellou, M Samama
Annales De Biologie Clinique
|
October 7, 2000
[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time]
A Kher, I Gouin, M M Samama
Thrombosis and Haemostasis
|
February 15, 1979
Urokinase i and ii activity
M Samama, B Cazenave, A M Otero
Archives Des Maladies Du Coeur Et Des Vaisseaux
|
January 1, 1995
[Current biological surveillance of oral anticoagulant treatment]
G Helft, A Vacheron, M M Samama
Page
of 68
Search research articles
Search
Showing results (181-190 of 677) with videos related to
Sort By:
Page
of 68
Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology
|
January 1, 1979
Blood coagulation and platelet function: introduction
B B Vargaftig, J Conard, M Samama
Journal Des Maladies Vasculaires
|
November 1, 1996
[Forensic medical implications of anticoagulant treatments]
M Samama, J C Valdes, J Natali
British Journal of Haematology
|
March 2, 1999
Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
L Bara, A Planes, M M Samama
International Angiology : a Journal of the International Union of Angiology
|
March 1, 1995
Red cell aggregability increases with the severity of venous insufficiency
A Chabanel, F Zuccarelli, M M Samama
Thrombosis Research
|
September 1, 1991
Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro
A M Dosne, F Dubor, M Samama
Annales De Medecine Interne
|
January 1, 1986
[Treatment of deep venous thromboses with heparin. Therapeutic management and biological monitoring]
J Conard, M H Horellou, M Samama
Acta Chirurgica Scandinavica. Supplementum
|
January 1, 1988
Incidence of thromboembolism in association with congenital disorders in coagulation and fibrinolysis
J Conard, M H Horellou, M Samama
Annales De Biologie Clinique
|
October 7, 2000
[Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time]
A Kher, I Gouin, M M Samama
Thrombosis and Haemostasis
|
February 15, 1979
Urokinase i and ii activity
M Samama, B Cazenave, A M Otero
Archives Des Maladies Du Coeur Et Des Vaisseaux
|
January 1, 1995
[Current biological surveillance of oral anticoagulant treatment]
G Helft, A Vacheron, M M Samama
Page
of 68